Alanyl-glutamine improves pancreatic β-cell function following ex vivo inflammatory challenge

Vinicius Fernandes Cruzat1, Kevin Noel Keane1, Anita Lavarda Scheinpflug1, Robson Cordeiro1, Mario J Soares2 and Philip Newsholme1

1School of Biomedical Sciences, and 2Directorate of Nutrition, Dietetics and Food Technology, School of Public Health, Curtin Health Innovation Research Institute of Ageing and Chronic Disease - Curtin University, GPO Box U1987, Perth, Western Australia, Australia 6845

Correspondence should be addressed to V F Cruzat
Email vinifer@usp.br or vinicius.cruzat@curtin.edu.au

Abstract

Obesity-associated diabetes and concomitant inflammation may compromise pancreatic β-cell integrity and function. L-glutamine and L-alanine are potent insulin secretagogues, with antioxidant and cytoprotective properties. Herein, we studied whether the dipeptide L-alanyl-L-glutamine (Ala-Gln) could exert protective effects via sirtuin 1/HUR (SIRT1/HUR) signalling in β-cells, against detrimental responses following ex vivo stimulation with inflammatory mediators derived from macrophages (IMMs). The macrophages were derived from blood obtained from obese subjects. Macrophages were exposed (or not) to lipopolysaccharide (LPS) to generate a pro-inflammatory cytokine cocktail. The cytokine profile was determined following analysis by flow cytometry. Insulin-secreting BRIN–BD11 β-cells were exposed to IMMs and then cultured with or without Ala-Gln for 24 h. Chronic insulin secretion, the L-glutamine–glutathione (GSH) axis, and the level of insulin receptor β (IR-β), heat shock protein 70 (HSP70), SIRT1/HUR, CCAAT-enhancer-binding protein homologous protein (CHOP) and cytochrome c oxidase IV (COX IV) were evaluated. Concentrations of cytokines, including interleukin 1 β (IL1β), IL6, IL10 and tumour necrosis factor alpha (TNFα) in the IMMs, were higher following exposure to LPS. Subsequently, when β-cells were exposed to IMMs, chronic insulin secretion, and IR-β and COX IV levels were decreased, but these effects were partially or fully attenuated by the addition of Ala-Gln. The glutamine–GSH axis and HSP70 levels, which were compromised by IMMs, were also restored by Ala-Gln, possibly due to protection of SIRT1/HUR levels, and a reduction of CHOP expression. Using an ex vivo inflammatory approach, we have demonstrated Ala-Gln-dependent β-cell protection mediated by coordinated effects on the glutamine–GSH axis, and the HSP pathway, maintenance of mitochondrial metabolism and stimulus–secretion coupling essential for insulin release.

Key Words

- diabetes
- glutamine
- alanine
- GSH
- HSP
- sirtuin 1

Introduction

The prevalence of diabetes, especially type 2 diabetes mellitus (T2DM), is continuing to rise at rapid rates (Whiting et al. 2011). In turn, obesity and metabolic syndrome are significant risk predictors for T2DM (Pradhan 2007). The conditions that underscore T2DM include a chronic pro-inflammatory state that, together with the adverse effects of hyperglycaemia and hyperlipidaemia, leads to progressive mitochondrial and pancreatic β-cell dysfunction (Akude et al. 2011, Kim et al. 2014). Chronic inflammation is characterised by...
enhanced cytokine levels (e.g. interleukin 1β (IL1β), IL6, IL10 and tumour necrosis factor alpha (TNFα)), and oxygen free radicals generated by immune cells, such as activated macrophages (Nackiewicz et al. 2014).

While many amino acids can potentially affect β-cell integrity, a relatively small number enhance insulin secretion in the presence of glucose; these include l-glutamine and l-alanine (Cunningham et al. 2005, Newsholme et al. 2014). Both amino acids are also important for the synthesis of the tripeptide l-γ-glutamyl-l-cysteinylglycine (GSH, i.e. a major component of the l-glutamine–GSH axis; Cunningham et al. 2005, Cruzat et al. 2014a, Petry et al. 2014). GSH has many protective functions in cellular metabolism, as well as attenuation of oxidative stress and inflammation under catabolic situations (Cruzat & Tirapegui 2009, Cruzat et al. 2014b). Furthermore, l-glutamine is a potent modulator of the heat shock protein (HSP) response, possibly through the activation of the glucosamine biosynthetic pathway (HBP) and nutrient sensors such as sirtuin 1 (SIRT1) (Newsholme et al. 2014). Interestingly, in T2DM patients, the concentration of the most abundant amino acid in the body, l-glutamine, may be reduced (approximately 20%), when compared with concentrations in healthy subjects (Menge et al. 2010, Tsi et al. 2012). In addition, in fatty diabetic animal models, the gluconeogenic amino acids, which include l-glutamine, are progressively reduced in plasma, liver and skeletal muscle (Wijekoon et al. 2004).

On the other hand, SIRT1 downstream pathways may be suppressed in chronic inflammatory situations, contributing to chronic low-grade inflammation and impaired insulin secretion (Luu et al. 2013). Hence, l-glutamine together with l-alanine supplied as the L-alanyl-l-glutamine dipeptide (Ala-Gln) may benefit the antioxidant system, attenuating inflammation, and may modulate the HSP response in catabolic situations (Cruzat et al. 2014a,b, Newsholme et al. 2014). A metabolic hallmark of diabetes is the aberrant alteration of glucose and lipid concentrations in the blood. Amino acids including glutamine (decreased) and branched-chain amino acids (increased) are known to be altered in diabetes, but the effects of Ala-Gln have never been tested on β-cells in the presence or absence of inflammatory mediators, which can be obtained from macrophages following stimulation in vitro (IMMs). The monocytes/macrophages used in this study were isolated from obese humans. Our novel experimental model was designed to provide an ex vivo pancreatic islet environment that mimics the effects of obesity-associated inflammation on β-cell dysfunction in vivo.

### Materials and methods

**Stimulation of macrophages isolated from blood, to produce inflammatory factors**

This study was conducted using macrophages circulating in the blood from 20 obese participants (eight men and 12 women, age 39 ± 13, BMI 36.5 ± 4.6 kg/m², body fat 49.3 ± 5.6% and HOMA–IR 3.12 ± 1.33). Dual-energy X-ray absorptiometry (Prodigy model, Lunar Radiation Corporation, Madison, WI, USA) was used to evaluate body composition. Plasma glucose and insulin were analysed by PathWest Laboratory, Royal Perth Hospital. All the procedures were approved by the Human Research Ethics Committee of Curtin University, Perth, Western Australia (protocol number HR 108/2013).

For the purposes of this research, the blood was collected in EDTA tubes and the peripheral blood mononuclear cells (PBMCs, a mixture of monocytes and lymphocytes) and neutrophils isolated using Histopaque 1077 (Sigma–Aldrich). After collection, blood was diluted in 2 mM EDTA PBS (1:2), and this suspension was layered onto 1:1 Histopaque and then centrifuged for 20 min at 600 g at room temperature. The PBMCs were collected from the interphase and washed three times with PBS and centrifuged for 10 min each at 300, 200 and 120 g at room temperature. The PBMCs were maintained in DMEM without phenol red (Life Technologies), supplemented with 10% (v/v) FCS, 0.1% antibiotics (100 U/ml penicillin and 0.1 mg/ml streptomycin), 5.56 mM d-glucose (pH 7.4), 110 mg/l sodium pyruvate, and 2 mM of Ala-Gln (Sigma–Aldrich). To allow the adherence of monocytes onto the 24-well plates, the PBMCs were maintained for 3 h in a humidified atmosphere of 5% CO₂ and 95% air at 37 °C.

Afterwards, the supernatant medium containing lymphocytes (approximately 98%) was removed. After washing with PBS, the adherent monocytes in the 24-well plate (2.0 × 10⁸ cells/well) were exposed to DMEM culture medium with and without 1 mM of lipopolysaccharide (LPS from Escherichia coli, strain 0111:B4, Sigma–Aldrich). After 3 h of stimulation, the media were removed and the adhered cells were washed with PBS. The monocytes/macrophages were subsequently incubated for a further 24 h in DMEM culture medium to obtain IMM- (macrophages not exposed to LPS) and IMM+ (macrophages exposed to LPS, see Fig. 1), and stored at −80 °C for subsequent experiments.

### Culture and treatment of β-cells

In this study, clonal insulin-secreting BRIN–BD11 pancreatic β-cells were utilised, on the basis of their well-characterised...
responses to glucose and amino acids, as well as their reproducible secretory responses, consistent receptor/signalling protein levels and cell survival/death responses (Cunningham et al. 2005, Corless et al. 2006, Kiely et al. 2007, McClenaghan 2007, Krause et al. 2011, 2014). After culture in vented 75-cm² flasks, cells were seeded in 24-well plates (1.0 × 10⁵ cells/well) and maintained for 24 h in a humidified cell culture incubator with 5% CO₂ and 95% air at 37°C. After this period, β-cells were exposed for 24 h to DMEM (Life Technologies) supplemented with 2 mM Ala-Gln containing IMM K or IMM C. This period was chosen because chronic inflammation has been implicated in β-cell dysfunction typical of T2DM (Krause et al. 2011). After inflammatory challenge, cells were washed with PBS and maintained for 24h in IMM-free DMEM media but with and without 2 mM Ala-Gln. Only in this last 24 h period, cells not receiving IMM (no IMM) were incubated under the same conditions with and without Ala-Gln for comparison purposes with the groups receiving IMM − or IMM +.

Quantification of specific inflammatory factors in the IMM using flow cytometric analyses

The inflammatory cytokines in the DMEM containing IMM − and IMM + (Fig. 2) were determined using flow cytometric analysis performed on an Attune Acoustic Focusing Cytometer (FACS, Applied Biosystems). Briefly, after LPS stimulation, macrophage supernatant was incubated for 15 min with 50 μl of an antibody mixture against specific cytokines. Samples were prepared and stained for flow cytometric analysis using the antibodies for IL1β, IL6, IL8, IL10 and TNFα (BD Cytometric Bead Array, CBA, San Jose, CA, USA). Data were analysed using the FACS Software FlowJo (TreeStar, Ashland OR, USA).

Measurement of chronic insulin secretion by β-cells

Following the last 24 h period, an aliquot of the medium was removed for insulin assay and quickly stored at −80°C for determination later. Insulin was measured...
using the Mercodia Ultrasensitive Rat Insulin ELISA Kit (Mercodia, Uppsala, Sweden).

**Cell viability measurements**

Following the experimental procedures described earlier, media were removed, and cells were washed with PBS and stained with Neutral Red (100 µg/ml of PBS). After 4 h of incubation, neutral red solution was removed and extracted with acid ethanol (alcohol/glacial acetic acid, 50:1 v/v). The absorbance was measured at a wavelength of 540 nm using a spectrophotometer (EnSpire Multimode Plate Reader, PerkinElmer, Waltham, MA, USA). The 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay was performed as described by Mosmann (1983), and the absorbance was measured at a wavelength of 550 nm.

**Measurement of the l-glutamine–GSH axis and GSH disulphide**

Intracellular l-glutamine and l-glutamate concentrations were determined in β-cell lysates using a commercial kit (Sigma–Aldrich) as described by Lund (1986). BRIN–BD11 cells were exposed to various conditions as described earlier in a 96-well plate (8.0×10³ cells/well) and GSH and GSH disulphide (GSSG) were detected using a luminescence-based system (GSH/GSSG-Glo Assay, Promega), and microplate luminometer (EnSpire Multimode Plate Reader) as described by Akerboom & Sies (1981).

**Western blotting analysis**

Following treatment, BRIN–BD11 cells were lysed in 100 µl of RIPA lysis buffer containing protease and phosphatase inhibitors (Cell Signaling Technology, Danvers, MA, USA). Cell lysates were transferred to ice-cold microcentrifuge tubes and centrifuged at 14 000 g for 10 min at 4 °C and stored at –80 °C. Cellular protein concentrations were quantified using the Direct Detect assay-free sample card and measured in the Direct Detect Infra-red Spectrometer (EMD Millipore, Billerica, MA, USA).

Equal amounts of protein were combined with lithium dodecyl sulphate (LDS) sample buffer and the reducing agent dithiothreitol (DTT, Novex, Life Technologies). Proteins (26 µg/lane) were subjected to SDS–PAGE, using 4–20% Tris-glycine gels, and transferred onto nitrocellulose membrane using iBlot transfer stacks (Life Technologies). The SNAP i.d. (EMD Millipore) quick immunoblot vacuum system was used for immunological detection and membranes were blocked in 3.0% (w/v) BSA (Amresco, Solon, OH, USA) in PBS–Tween (PBST, 1% w/v) buffer. Membranes were incubated for 10 min with the primary antibodies SIRT1 (1:1000), HSP70 (1:1000), cytochrome c oxidase subunit IV (COX IV, 1:1000), insulin receptor β and pro-insulin receptor (IR-β and PRO-IR respectively, 1:1000), CCAAT-enhancer-binding protein homologous protein (CHOP, 1:500) and ELAVL1/HUR (1:300). The anti-rabbit IgG (Agilent’s Dako, Glostrup, Denmark) diluted 1:2000 was used as a secondary antibody. An anti-rabbit β-actin (1:1000) was used as a control for protein loading. All of the primary antibodies were diluted in 3% BSA-PBST buffer.

---

**Figure 2**

IMM content determined by flow cytometric analysis. Macrophages in 24-well plates (2.0×10⁶ cells/well) were exposed or not to LPS for 3 h (IMM+ and IMM− respectively), then washed and maintained for further 24 h in DMEM culture medium with Ala-Gln to generate the cytokine cocktail. (A) Interleukin 1β (IL1β), (B) IL6, (C) IL8, (D) IL10 and (E) tumour necrosis factor alpha (TNFα). *P<0.0001 for the comparison with IMM−.
antibodies were obtained from Cell Signaling Technology. Membranes were visualised with Clarity Western ECL substrate (Bio-Rad) in the Molecular Imager Gel Doc XR System (Bio-Rad).

**Statistical analysis**

Statistical differences between the IMM levels in the DMEM culture media were detected using the two-tailed unpaired parametric t-test ($P<0.0001$). Following confirmation of a normal distribution using Kolmogorov–Smirnov test, β-cell results were subjected to ANOVA (one way). Whenever $P$ values were ≤0.05, post-hoc tests employed the multiple comparison procedure of Tukey (Tukey Honestly Significant Difference (HSD)). All statistical calculations and graphics were performed using the GraphPad Prism Software v. 6.0 (La Jolla, CA, USA).

**Results**

**Identification of IMMs isolated from obese humans**

Once isolated from obese human blood, monocytes/macrophages were incubated in the presence or absence of LPS for 3 h, and then incubated for a further 24 h in DMEM with 2 mM Ala-Gln to allow for increased cytokine secretion before determination of the composition of IMMs. As depicted in Fig. 2, all cytokine levels (IL1β, IL6, IL8, IL10 and TNFα) were higher ($P<0.0001$) in the IMM+ group (LPS-stimulated), when compared with the IMM− group, which may mimic the status of inflammation during the progression of T2DM. In this phase of the experimental protocol, both IMM− and IMM+ cells were generated in DMEM supplemented with Ala-Gln.

**Effect of IMMs on β-cell integrity and function**

Inflammation of the islet is associated with the pathophysiology of diabetes. However, the majority of the in vitro studies utilise synthetic cytokine cocktails for cell stimulation. This study represents a novel approach, i.e. challenging β-cells with inflammatory mediators obtained from ex vivo macrophages (IMMs). L-glutamine and l-alanine are crucial for insulin secretion and can be consumed at high rates by both islets and β-cells. As depicted in Fig. 3A, the absence per se of 2 mM Ala-Gln in the culture media of β-cells dramatically decreased chronic (24 h) insulin secretion (by 78%) in the non-inflammatory-stimulated (no IMM) groups ($P<0.05$). A similar effect was observed in cells exposed to both IMM− and IMM+ in the media without Ala-Gln during the last 24 h. Insulin secretion was 80 and 87% lower, respectively, when compared with the no IMM group incubated with Ala-Gln ($P<0.05$). Interestingly, the reduction in insulin secretion from both groups of BRIN-BD11 exposed to both IMMs was attenuated by the availability of Ala-Gln ($P<0.05$). However, this effect was more pronounced (approximately 50% higher) in the IMM− group than in the IMM+ group ($P<0.05$). Moreover, in the IMM− group with Ala-Gln, the insulin secretion was also significantly ($P<0.05$) higher (4.5-fold) when compared with the no IMM group without the dipeptide (Fig. 3A).

Cell metabolic viability was reduced by 37% in the IMM-absent group without Ala-Gln, when compared with the IMM-absent group with Ala-Gln ($P<0.05$), indicating the importance of Ala-Gln for cell metabolism and
Table 1  Glutamine, glutamate, GSH and GSSG content of BRIN–BD11 pancreatic α-cells following IMM treatment and the effects of L-alanyl-L-glutamine (Ala-Gln). Data are presented as mean±s.e.m.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Experimental groups</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No IMM</td>
<td>IMM −</td>
<td>IMM +</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>− Ala-Gln</td>
<td>+ Ala-Gln</td>
<td>− Ala-Gln</td>
<td>+ Ala-Gln</td>
<td>− Ala-Gln</td>
</tr>
<tr>
<td>Glutamine (nmol/mg protein)</td>
<td>8.83±1.43</td>
<td>12.96±0.51*</td>
<td>2.70±1.05*†</td>
<td>10.22±0.86†</td>
<td>2.63±0.50*†</td>
</tr>
<tr>
<td>Glutamate (nmol/mg protein)</td>
<td>2.03±0.24</td>
<td>2.34±0.32</td>
<td>0.83±0.18</td>
<td>2.55±0.57†</td>
<td>0.86±0.37</td>
</tr>
<tr>
<td>GSH (µM)</td>
<td>1.85±0.15</td>
<td>4.15±0.14*</td>
<td>2.39±0.05†</td>
<td>4.19±0.17*†</td>
<td>2.50±0.22†</td>
</tr>
<tr>
<td>GSSG (µM)</td>
<td>0.41±0.04</td>
<td>0.37±0.02</td>
<td>0.29±0.02</td>
<td>0.31±0.02</td>
<td>0.27±0.01</td>
</tr>
<tr>
<td>GSH/GSSG</td>
<td>5.06±0.49</td>
<td>11.63±1.01*</td>
<td>7.95±0.45†</td>
<td>12.08±0.62†</td>
<td>8.05±0.49†</td>
</tr>
</tbody>
</table>

*P<0.05 for the comparison with no IMM group without Ala-Gln. †P<0.05 for the comparison with no IMM with Ala-Gln. ‡P<0.05 Ala-Gln effects on both IMM − and IMM + groups.

function (Fig. 3B). Moreover, in the absence of Ala-Gln, IMM− and IMM+ exposure decreased viability as assessed by MTT (by 28 and 48%, P<0.05), when compared with the IMM-absent group but in the presence of dipeptide. Nevertheless, the cellular metabolic activity in both groups of BRIN–BD11 cells exposed to IMMs was partially restored (by 30%) by the presence of Ala-Gln (P<0.05). When compared with the IMM-absent group without Ala-Gln, viability levels as assessed by MTT were higher (P<0.05) in the Ala-Gln exposed BRIN–BD11 cells exposed to IMM− media (Fig. 3B). No differences were observed in the quantitative estimation of cell numbers by neutral red uptake assay (Fig. 3C).

The importance of the β-cell L-glutamine–GSH axis and redox state

Ala-Gln effects in no IMM groups  Although inflammation is involved in β-cell dysfunction, a reduction per se in the availability of L-glutamine and L-alanine, both important L-glutamate precursors required for GSH synthesis, may make β-cells vulnerable to oxidative stress. Indeed, L-glutamine concentrations in no IMM groups was decreased in the absence of Ala-Gln (by 32%, P<0.05, Table 1). This affected the availability of GSH, which was lowered by 55% in the group without Ala-Gln (P<0.05). While no differences were observed in the GSSG content, the GSH-to-GSSG ratio (GSH/GSSG), an index of intracellular redox status was 56% lower in the absence of Ala-Gln (P<0.05, Table 1). These results indicate that in the absence of Ala-Gln, a harmful intracellular oxidative environment was promoted.

Effects of IMMs and evidence of Ala-Gln protection  BRIN–BD11 cells in the absence of Ala-Gln but exposed to both IMM− and IMM+ were associated with reduced L-glutamine concentration, by almost 70%, when compared with both IMM-absent groups (P<0.05, Table 1). This effect lowered GSH concentration (by approximately 40%) and GSH/GSSG ratio (by approximately 30%), observed in β-cell groups exposed to IMMs, when compared with the no IMM group with Ala-Gln (P<0.05).

On the other hand, the addition of Ala-Gln to the β-cells was able to restore L-glutamine and L-glutamate levels in both groups exposed to IMMs (P<0.05). Moreover, in both IMM groups, the pro-oxidative situation was reversed (P<0.05) by the addition of the dipeptide to the β-cells, as assessed by GSH content (increased by 31%) and the GSH/GSSG ratio (by almost 34%). This GSH response was also higher (P<0.05) than that in the IMM-absent group without Ala-Gln (Table 1).

Effects of IMMs and Ala-Gln on protein expression of β-cells  The exposure of β-cells exposure to both IMM− and IMM+ reduced IR-β levels by approximately 60% (P<0.05; Fig. 4C), in the absence of Ala-Gln, when compared with the IMM-absent group, supplemented with Ala-Gln. However, the availability of the dipeptide in both IMM-treated groups reversed this scenario by increasing IR-β, and this effect was much greater (P<0.05) in the IMM+ group with Ala-Gln, compared with the IMM-absent group incubated without Ala-Gln. Conversely, the presence of Ala-Gln lowered the expression of PRO-IR by 58% (Fig. 4A) in the IMM-absent group, and at least 45% in BRIN–BD11 cells exposed to both IMMs, when compared with the IMM-absent group incubated without Ala-Gln (P<0.05). Lower PRO-IR levels were also observed in cells exposed to IMM− and IMM+ and incubated with Ala-Gln compared with the respective
groups without Ala-Gln. Moreover, both IMM-treated groups without Ala-Gln presented higher PRO-IR expression, when compared with the IMM-absent group incubated with dipeptide (P<0.05).

As expected, the absence of Ala-Gln per se increased CHOP expression (by almost 50%), a marker of endoplasmic reticulum (ER) stress, in the IMM-absent groups (P<0.05, Fig. 4B). The same effect was observed in the groups exposed to both IMM– and IMM+ in cells incubated without Ala-Gln (P<0.05). Interestingly, when Ala-Gln was added to the β-cells exposed to IMM–, CHOP levels were lower (by 42%) than those in the corresponding group incubated without Ala-Gln (P<0.05). Despite this effect, the CHOP level was still elevated (by almost 45%) in the IMM+ group incubated with Ala-Gln, when compared with the IMM-absent group incubated with Ala-Gln (P<0.05), possibly a consequence of the high content of cytokines in the IMM+ group. Furthermore, COX IV levels were lower (almost 53%) in all groups of BRIN–BD11 cells incubated in the absence of Ala-Gln (P<0.05, Fig. 4D). Conversely, incubation in the presence of Ala-Gln reversed this scenario (P<0.05), thus maintaining COX IV levels.

The nutrient-dependent modulators, SIRT1, HUR and HSP70 (the major HSP), were reduced (by 55, 66 and 75% respectively) in the IMM-absent group incubated without Ala-Gln, when compared with the same conditions with the dipeptide (P<0.05, Fig. 5A, C and B respectively).

Furthermore, in cells incubated without Ala-Gln, but exposed to both IMM– and IMM+, almost 50% lower expression of these proteins occurred, compared with the IMM-absent group incubated with Ala-Gln (P<0.05). However, in the presence of both IMM– and IMM+, addition of Ala-Gln to the β-cells reversed this scenario (P<0.05), by increasing SIRT1, HUR and HSP70 levels, compared with cells incubated without Ala-Gln (P<0.05). The summary of the beneficial effects of Ala-Gln on β-cell function and protein expression following inflammatory challenge is provided in Table 2.

**Discussion**

Inflammation is an adaptive and protective response of multicellular organisms against infections. On the other hand, chronic metabolic diseases, such as obesity and T2DM, are characterised by meta-inflammation, wherein elevation of several pro-inflammatory cytokines induces changes in metabolic functioning and homeostatic set points that may underscore the progression of obesity to diabetes (Medzhitov 2010). The objective of this study was to try and mimic the inflammatory milieu in vivo not only to understand how β-cell function and integrity were affected by a low or high dose of cytokines, but also to discover whether the dipeptide Ala-Gln had protective effects with respect to insulin secretion, signal transduction and other functional parameters affected...
by these cytokines. Using a novel approach, where monocytes/macrophages were isolated from obese patients recruited in our clinic and used to generate a ‘cocktail’ of inflammatory cytokines ex-vivo in the basal (unstimulated) state or after stimulation with LPS, subsequent functional effects of the cytokine cocktail on \( \beta \)-cells were then compared with a control treatment, where \( \beta \)-cells were not exposed to cytokines (as shown in Fig. 1). The effects of the cytokine cocktail (IMMs) on \( \beta \)-cell function and integrity have never been studied before, to the best of our knowledge. However, we recognise the limitations of our study, in that we did not isolate monocytes/macrophages from lean human volunteers and we have used a rat clonal \( \beta \)-cell line rather than human cells, as no equivalent human \( \beta \)-cell line (in terms of magnitude of metabolic, signalling and secretory responses) is currently available. However, it has been reported previously that the major human pro-inflammatory cytokine, IL1\( \beta \), elicited potent suppression of insulin secretion in both human and rat islet cells (Kawahara & Kenney 1991).

As expected, when the monocytes/macrophages obtained from obese participants were exposed to a pro-inflammatory stimulant (LPS), the release of IL1\( \beta \), IL6, IL8, IL10 and TNF\( \alpha \) increased significantly. In response to inflammation, the \( \beta \)-cell undergoes protective changes, that enhance survival but at the expense of insulin secretion (Kahn et al. 2006, Richardson et al. 2009, Jourdan et al. 2013). In these scenarios, l-glutamine is particularly important for ensuring adequate levels of protection and insulin secretion (Corless et al. 2006). In this study, the availability of l-glutamine through the addition of Ala-Gln resulted in attenuation of the negative effects of IMM exposure, with respect to insulin secretion (Fig. 3A). These results are in agreement with results from previous studies (Corless et al. 2006), in which l-glutamine availability for BRIN–BD11 cells resulted in optimisation of insulin secretion and was associated with up-regulation of 148 genes by at least 1.8-fold and down-regulation of 18 genes related to insulin signalling and metabolism.

Recent reports have described reductions in circulating levels of l-glutamine in diabetes (Etgen & Oldham 2000, Wijekoon et al. 2004, Menge et al. 2010, Tsai et al. 2012). The absence of 2 mM Ala-Gln lowered cellular l-glutamine levels and compromised the GSH concentration in the \( \beta \)-cells as described herein (Table 1). This study does not reveal whether the observed beneficial effects of Ala-Gln are mediated by l-glutamine or l-alanine. However, it has been previously reported that both amino acids are precursors of l-glutamate for de novo GSH generation (Rutten et al. 2005, Cruzat & Tiraepgui 2009), providing protection against oxidative

![Figure 5](image-url)

**Figure 5**

SIRT1 (A), HSP70 (B) and HUR (C) protein levels obtained from BRIN–BD11 \( \beta \)-cells following IMM challenge with or without Ala-Gln were measured by Western blot analysis. Data are expressed as mean ± S.E.M. for the comparison with the no IMM group without Ala-Gln. For the comparison with the no IMM group with Ala-Gln, \( P<0.05 \) Ala-Gln effects on both IMM– and IMM+ groups.

Table 2  The beneficial effects of incubation in the presence of Ala-Gln (compared with absence) on \( \beta \)-cell function and protein expression following an inflammatory challenge

<table>
<thead>
<tr>
<th>Parameters</th>
<th>IMM–</th>
<th>IMM+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin secretion</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>IR-( \beta )</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>PRO-IR</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>HSP70</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>SIRT1</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>HUR</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>CHOP</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>COX IV</td>
<td>↑</td>
<td>↓</td>
</tr>
</tbody>
</table>
stress and inflammation (Cruzat et al. 2010, 2014a, Krause et al. 2011, Petry et al. 2014). GSH acts as a scavenger system and has the ability to counteract reactive oxygen species (ROS, e.g. hydrogen peroxide) by reducing peroxides, protecting cell membranes and reducing lipid peroxidation. As a cause or consequence, oxidative stress has been suggested to play an integral part in the pathogenesis of various organ dysfunctions and disease (Pradhan 2007, Newsholme et al. 2009, Krause et al. 2014).

GSH redox coupling systems are critical to β-cell integrity and function, as these cells express low levels of ROS-metabolising enzymes, such as catalase and glutathione peroxidase (Tiedge et al. 1997, Takahashi et al. 2014). The GSH oxidation ratio (GSH redox potential – E_GSH) is an indicator of the balance between protein thiol oxidation and the ability to reduce them with GSH making use of NADPH as an electron donor to convert GSSG back to GSH (Cruzat & Tirapegui 2009, Newsholme et al. 2009). In fact, without the presence of Ala-Gln, the GSH/GSSG ratio was low under all conditions tested (Table 1), which makes the β-cells more vulnerable to oxidative stress. However, we have demonstrated herein that Ala-Gln supplementation in the media reinforces the substrate availability for maintenance of the GSH/GSSG ratio, favouring a reduced state. This finding can be particularly important, as excessive production of ROS alters the function of voltage-dependent channels, such as ATP-sensitive K⁺-channels, electron transport chain proteins and essential components for insulin exocytosis (Newsholme et al. 2009, Krause et al. 2011). The pro-oxidant state promoted by both IMMs decreased IR-β levels, possibly due to the lack of insulin secretion (i.e. autocrine/paracrine effect), which also promoted an inversely PRO-IR concentration (Fig. 4C and A respectively). However, the presence of Ala-Gln reversed this scenario.

Mitochondrial oxidative stress and the subsequent effects on ATP synthesis are one of the most important mechanisms responsible for a reduction in insulin secretion in T2DM. COX IV is required to catalyse the reduction of molecular oxygen to water coupled to the translocation of protons across the mitochondrial inner membrane to the matrix, which drives ATP synthesis. Diabetic animal models (Akude et al. 2011) and other inflammatory scenarios display lower COX IV expression and decreased respiratory chain activity (Hahn et al. 2014, Krause et al. 2014). In turn, this contributes to abnormalities in cellular energy metabolism and a lowering of insulin secretion (Akude et al. 2011, Hahn et al. 2014). Our results are in agreement with these findings, as the absence of Ala-Gln per se, and exposure to IMM⁺ and IMM⁻ decreased COX IV levels (Fig. 4D).

In order to protect the cell against diverse environmental and stress-inducing situations, such as ischaemia, inflammation and oxidative stress, the HSP response is an organised conservative genetic mechanism that acts as a molecular chaperone, preventing the accumulation of misfolded proteins. Moreover, expression of HSP is now widely accepted as anti-inflammatory in action, as it blocks the cyclic activation and nuclear binding of nuclear factor κB (NFκB) to the promoters of inflammatory genes that could otherwise compromise cell integrity and function. Thus, HSP attenuates unresolved inflammation (Newsholme & de Bittencourt 2014). Amino acids, such as L-glutamine, are required for the optimal HSP70 response, through the HBP-induced activation of SIRT1/HUR (Lafontaine-Lacasse et al. 2011, Newsholme et al. 2014), which was observed in our study (Fig. 5A and C respectively). Enhanced HUR may promote the stability of numerous target mRNAs, including that encoding SIRT1, via association of HUR with the 3′-untranslated region of Sirt1 mRNA, that promotes its stability and thus a rise in Sirt1 expression (Newsholme & de Bittencourt 2014). In turn, SIRT1 enhances the expression of the main heat shock factor, HSF1, and heat shock elements (HSEs) in the nuclei, resulting in expression of HSP70 (Kotas et al. 2013, Cruzat et al. 2014a, Petry et al. 2014), as observed herein (Fig. 5B).

In contrast, SIRT1 can suppress inflammation and stimulate HSP responses; however, in response to chronic inflammation, similar to that in obesity-associated diabetes, the SIRT1/HUR axis is repressed (Kotas et al. 2013), contributing to the unresolved inflammation (Lafontaine-Lacasse et al. 2011, Luu et al. 2013). In this study, using our in vitro model to mimic in vivo inflammation, we observed that Ala-Gln maintained the HSP70 levels via the SIRT1/HUR axis. This is a protective effect as reduced levels of HSP70 in obesity-associated diabetes are correlated with reduced insulin sensitivity, hyperglycaemia and hyperinsulinaemia (Chung et al. 2008). Moreover, inflammation in obesity is related to ER stress (Hummasti & Hotamisligil 2010), and this in turn, plays a central role in the development of insulin resistance and diabetes (Ozcan et al. 2006). In response to such conditions, cells react to ER dysfunction by increasing the expression of CHOP, which has observed in our study (Fig. 4B). Interestingly, the absence of Ala-Gln per se enhanced CHOP, indicating an important role for amino acids in the control of ER stress. Some reports have described increased levels of CHOP in insulitis (Marhfour et al. 2012) and depletion of
GSH (Kim et al. 2008), which increases the production of ROS in the ER. However, our results indicated that even with increased levels of CHOP, GSH was restored in the Ala-Gln groups with and without IMM.

Although significant progress has been made in understanding the pathogenesis of diabetes, the prevalence of the condition is continuously rising and will challenge health care systems worldwide in the 21st century. Many of the underlying molecular mechanisms are still unknown, and consequently new effective treatments are elusive. In this study, we have provided evidence for the importance of amino acids and related dipeptides, e.g. Ala-Gln, for β-cell integrity and function following inflammatory challenge (Table 2). The effects observed herein are mediated via intermediary metabolism, mitochondrial function, and antioxidant and HSP responses. Our work may have implications for development of novel in vivo approaches, with the aim of protecting β-cell function.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
V F C was in receipt of postdoctoral fellowship from the Brazilian National Council for Scientific and Technological Development (CNPq – Science Without Borders Programme, process 245562/2012-5).

Author contribution statement
This work was designed by V F C, K N K and P N. The initial manuscript and drafts were prepared by V F C and revised by V F C, K N K and P N. Patients were recruited and the measurements were carried out in the laboratory of M J S. Body composition data were obtained by M J S. All experiments and biochemical analyses were performed by V F C and K N K. A L S and R C contributed to western blot analysis of IR-β and PRO-IR protein levels. Data and statistical analyses and figure preparation were performed by V F C. Supervision of the experimental work and manuscript preparation were performed by P N and M J S. All authors approved the final version of the paper.

Acknowledgements
The authors thank Curtin University School of Biomedical Sciences and the School of Public Health and Faculty of Health Sciences for research support. They also thank Prof. Paulo Ivo Homem de Bittencourt Jr and Ms Graziella Nicoletti for the discussions and interest.

References


Ettgen GJ & Oldham BA 2000 Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49 684–688. (doi:10.1016/S0026-0495(00)008049-9)


Newsholme P, Morgan D, Rebelato E, Oliveira-Emilio HC, Procopio J, Curi R & Carpinelli A 2009 Insights into the critical role of NADPH oxidase(s) in the normal and dysregulated pancreatic β cell. Diabetologia 52 2489–2498. (doi:10.1007/s00125-009-1556-z)


Downloaded from Bioscientifica.com at 09/15/2023 09:41:10AM via free access